Fred Hutch Cancer Center | Strategic Alliance Partners

Sonrotoclax plus zanubrutinib drove durable remissions across IGHV-mutated and del(17p)/TP53 CLL subgroups in an updated phase 1/1b analysis.

Experts highlight some of the top hematologic oncology data presented at ASCO 2026, including key studies in multiple myeloma and diffuse large B-cell lymphoma.

Experts outline the key multiple myeloma presentations they are anticipating at the 2026 EHA Congress.

Treatment with gedatolisib-based regimens led to significant PFS benefits vs alpelisib/fulvestrant in PIK3CA-mutant HR-positive advanced breast cancer.

Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care.

Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS.

Dr Shadman discusses an indirect comparison evaluating zanubrutinib vs acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

In a post hoc indirect comparison, data showed zanubrutinib was linked to improved PFS vs acalabrutinib/venetoclax in patients with treatment-naive CLL.

Mazyar Shadman, MD, MPH, discusses a post hoc analysis that compared data BTK inhibitor–based regimens for treatment-naive chronic lymphocytic leukemia.

Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with IMiDs.

Rahul Banerjee, MD, FACP, discusses key considerations and unanswered questions regarding the selection between KRd and VRd in newly diagnosed myeloma.

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Evan Y. Yu, MD, discusses the potential utility of AR degradation, mutation inhibition, and suppression for patients with metastatic prostate cancer.

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.